Health Technology Assessment Resource Centre, ICMR-National Institute of Epidemiology, Chennai, India.
Int J Rheum Dis. 2021 Mar;24(3):314-326. doi: 10.1111/1756-185X.14066. Epub 2021 Jan 23.
Region-specific health-related quality of life (HRQoL) scores or utility values are representative and pivotal for economic evaluations as they are influenced by the value judgment of the local population. This study systematically reviewed and pooled EuroQoL-5 Dimension (EQ-5D) utility scores of rheumatoid arthritis (RA) across primary studies from Asia.
Studies reporting EQ-5D utility scores among adult RA patients from Asian countries were systematically searched in PubMed-Medline, Scopus and Embase since inception through February 2020. Selected studies were systematically reviewed and study quality assessment was performed. Meta-analysis was performed using a random-effect model with subgroup and meta-regression analysis to explore heterogeneity.
Among 1391 searched articles, 37 studies with 31 983 participants were systematically reviewed and meta-analysis was conducted among 31 studies. The pooled EQ-5D scores and EQ-5D visual analog score were 0.66 (95% CI 0.63-0.69, I = 99.65%) and 61.21 (50.73-71.69, I = 99.56%) respectively with high heterogeneity. For RA patients with no, low, moderate and high disease activity based on Disease Activity Score (DAS)-28, the pooled EQ-5D scores were 0.78 (0.65-0.90), 0.73 (0.65-0.80), 0.53 (0.32- 0.74), and 0.47 (0.32-0.62), respectively. On meta-regression, age of patients (P < .05) was positively associated and use of glucocorticoids (P < .05) was inversely associated with utility values.
Lower EQ-5D scores were associated with severe disease activity, increasing age and female gender among RA patients. The study provides pooled EQ-5D scores for RA patients that are useful inputs for cost-utility studies in Asia.
特定区域的健康相关生活质量(HRQoL)评分或效用值是经济评估的代表性和关键指标,因为它们受到当地人群的价值判断的影响。本研究系统地回顾和汇总了亚洲原发性研究中类风湿关节炎(RA)的 EuroQoL-5 维度(EQ-5D)效用评分。
系统地检索了 PubMed-Medline、Scopus 和 Embase 自成立以来至 2020 年 2 月期间发表的亚洲国家成年 RA 患者的 EQ-5D 效用评分的研究。对选定的研究进行了系统回顾和研究质量评估。使用随机效应模型进行荟萃分析,并进行亚组和荟萃回归分析以探索异质性。
在 1391 篇搜索文章中,有 37 项研究共纳入 31983 名参与者进行了系统回顾和荟萃分析。汇总的 EQ-5D 评分和 EQ-5D 视觉模拟评分分别为 0.66(95%CI 0.63-0.69,I=99.65%)和 61.21(50.73-71.69,I=99.56%),具有高度异质性。基于疾病活动评分(DAS)-28,RA 患者无疾病活动、低疾病活动、中度疾病活动和高疾病活动的汇总 EQ-5D 评分分别为 0.78(0.65-0.90)、0.73(0.65-0.80)、0.53(0.32-0.74)和 0.47(0.32-0.62)。在荟萃回归中,患者年龄(P<.05)与效用值呈正相关,而糖皮质激素的使用(P<.05)与效用值呈负相关。
RA 患者的 EQ-5D 评分较低与疾病活动度严重、年龄增长和女性性别有关。本研究提供了 RA 患者的汇总 EQ-5D 评分,这是亚洲成本效用研究的有用输入。